Jump Financial LLC Has $317,000 Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Jump Financial LLC reduced its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 94.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,300 shares of the biopharmaceutical company’s stock after selling 191,700 shares during the period. Jump Financial LLC’s holdings in Royalty Pharma were worth $317,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its stake in shares of Royalty Pharma by 112.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 531 shares during the period. Allworth Financial LP lifted its holdings in shares of Royalty Pharma by 76.7% during the fourth quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 731 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Royalty Pharma by 485.2% in the 4th quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 1,999 shares in the last quarter. Rakuten Securities Inc. bought a new stake in shares of Royalty Pharma in the 4th quarter worth about $110,000. Finally, PNC Financial Services Group Inc. increased its position in shares of Royalty Pharma by 10.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 536 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Price Performance

Shares of RPRX opened at $26.62 on Friday. The stock has a 50 day simple moving average of $28.62 and a 200 day simple moving average of $28.62. The company has a debt-to-equity ratio of 0.62, a quick ratio of 12.52 and a current ratio of 12.52. Royalty Pharma plc has a 52-week low of $25.92 and a 52-week high of $34.65. The firm has a market capitalization of $15.90 billion, a PE ratio of 19.87, a P/E/G ratio of 3.50 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. The company had revenue of $568.00 million for the quarter, compared to analyst estimates of $671.45 million. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. During the same period in the previous year, the company posted $1.60 earnings per share. Sell-side analysts predict that Royalty Pharma plc will post 4.03 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.16%. The ex-dividend date of this dividend is Thursday, May 16th. Royalty Pharma’s dividend payout ratio is presently 62.69%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Bank of America lowered their target price on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. JPMorgan Chase & Co. lowered their target price on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. StockNews.com cut Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Finally, The Goldman Sachs Group cut their target price on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $46.75.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.